NASDAQ:SPRB Spruce Biosciences (SPRB) Stock Price, News & Analysis $0.57 +0.01 (+1.19%) (As of 07/5/2024 08:53 PM ET) Add Compare Share Share Today's Range$0.56▼$0.5850-Day Range$0.51▼$0.8552-Week Range$0.50▼$5.95Volume286,500 shsAverage Volume883,378 shsMarket Capitalization$23.53 millionP/E RatioN/ADividend YieldN/APrice Target$5.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Spruce Biosciences alerts: Email Address Spruce Biosciences MarketRank™ Stock AnalysisAnalyst RatingHold2.25 Rating ScoreUpside/Downside774.6% Upside$5.00 Price TargetShort InterestHealthy0.30% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.24) to ($1.03) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.48 out of 5 starsMedical Sector649th out of 879 stocksPharmaceutical Preparations Industry302nd out of 417 stocks 3.1 Analyst's Opinion Consensus RatingSpruce Biosciences has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on 2 buy ratings, 6 hold ratings, and no sell ratings.Amount of Analyst CoverageSpruce Biosciences has only been the subject of 2 research reports in the past 90 days.Read more about Spruce Biosciences' stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.30% of the outstanding shares of Spruce Biosciences have been sold short.Short Interest Ratio / Days to CoverSpruce Biosciences has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Spruce Biosciences has recently increased by 201.99%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldSpruce Biosciences does not currently pay a dividend.Dividend GrowthSpruce Biosciences does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for SPRB. Previous Next 0.0 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 1 news article for Spruce Biosciences this week, compared to 1 article on an average week.Search InterestOnly 3 people have searched for SPRB on MarketBeat in the last 30 days. This is a decrease of -40% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Spruce Biosciences to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Spruce Biosciences insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 9.10% of the stock of Spruce Biosciences is held by insiders.Percentage Held by Institutions91.71% of the stock of Spruce Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Spruce Biosciences' insider trading history. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Spruce Biosciences are expected to grow in the coming year, from ($1.24) to ($1.03) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Spruce Biosciences is -0.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Spruce Biosciences is -0.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSpruce Biosciences has a P/B Ratio of 0.30. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Spruce Biosciences' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad StocksToTradeWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made millionaire Tim Bohen is giving you an inside look at the megatrend that’s going to change everything.Discover the #1 company leading this revolution About Spruce Biosciences Stock (NASDAQ:SPRB)Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. Spruce Biosciences, Inc. has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses; and collaboration and license agreement with Kaken Pharmaceutical Co. Ltd. to develop, manufacture, and commercialize tildacerfont for the treatment of CAH in Japan. The company was incorporated in 2014 and is headquartered in South San Francisco, California.Read More SPRB Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SPRB Stock News HeadlinesJuly 7 at 2:14 AM | americanbankingnews.comSpruce Biosciences, Inc. (NASDAQ:SPRB) Receives $5.00 Average Price Target from BrokeragesJune 4, 2024 | businesswire.comSpruce Biosciences and HMNC Brain Health Announce Strategic Collaboration to Develop Treatment for Major Depressive Disorder (MDD)July 8, 2024 | Paradigm Press (Ad)Man who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… A predicted Trump would win. You won’t believe what he’s predicting now.June 3, 2024 | businesswire.comSpruce Biosciences Presented Phase 2 POWER Study Results of Tildacerfont for the Treatment of Polycystic Ovary Syndrome at ENDO 2024May 23, 2024 | finance.yahoo.comSpruce Biosciences to Participate in the Jefferies Global Healthcare ConferenceMay 23, 2024 | businesswire.comSpruce Biosciences to Participate in the Jefferies Global Healthcare ConferenceMay 16, 2024 | markets.businessinsider.comHold Rating on Spruce Biosciences Amid Clinical Trial Uncertainties and Rising CompetitionMay 16, 2024 | finance.yahoo.comSpruce Biosciences, Inc. (SPRB)July 8, 2024 | Paradigm Press (Ad)Man who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… A predicted Trump would win. You won’t believe what he’s predicting now.May 15, 2024 | markets.businessinsider.comBuy Rating Affirmed for Spruce Biosciences Amid Upcoming Trial Data and Strong Financial PositionMay 13, 2024 | msn.comSPRB Stock Earnings: Spruce Biosciences Beats EPS, Beats Revenue for Q1 2024May 13, 2024 | businesswire.comSpruce Biosciences Reports First Quarter 2024 Financial Results and Provides Corporate UpdatesApril 30, 2024 | finance.yahoo.comSpruce Biosciences Announces Additional Poster Presentation at the Pediatric Endocrine Society 2024 Annual MeetingApril 26, 2024 | investing.comSpruce Biosciences Inc (SPRB)April 22, 2024 | businesswire.comSpruce Biosciences Announces Upcoming Poster Presentation at the Pediatric Endocrine Society 2024 Annual MeetingApril 4, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Spruce Biosciences, Inc. - SPRBMarch 27, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Spruce Biosciences, Inc. - SPRBMarch 23, 2024 | finance.yahoo.comRevenue Downgrade: Here's What Analysts Forecast For Spruce Biosciences, Inc. (NASDAQ:SPRB)See More Headlines Receive SPRB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Spruce Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/13/2024Today7/07/2024Next Earnings (Estimated)8/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:SPRB CUSIPN/A CIK1683553 Webwww.sprucebiosciences.com Phone415-655-4168FaxN/AEmployees22Year FoundedN/APrice Target and Rating Average Stock Price Target$5.00 High Stock Price Target$10.00 Low Stock Price Target$2.00 Potential Upside/Downside+774.6%Consensus RatingHold Rating Score (0-4)2.25 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($1.13) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-47,920,000.00 Net Margins-461.67% Pretax Margin-461.67% Return on Equity-57.53% Return on Assets-43.45% Debt Debt-to-Equity Ratio0.02 Current Ratio4.67 Quick Ratio4.67 Sales & Book Value Annual Sales$10.09 million Price / Sales2.33 Cash FlowN/A Price / Cash FlowN/A Book Value$1.88 per share Price / Book0.30Miscellaneous Outstanding Shares41,150,000Free Float37,410,000Market Cap$23.53 million OptionableOptionable Beta2.41 Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesMr. Michael G. Grey (Age 71)Executive Chairman Comp: $70kDr. Javier Szwarcberg M.D. (Age 54)M.P.H., CEO & Director Comp: $951.85kMr. Samir M. Gharib CPA (Age 42)M.B.A., President & CFO Comp: $683.63kDr. Ralph William Charlton III (Age 54)M.D., Chief Medical Officer Comp: $647.4kMs. P. J. RamtinSenior Vice President of Business OperationsMs. Heidi Petersen M.P.H.Senior Vice President of Regulatory & QualityMore ExecutivesKey CompetitorsCellectar BiosciencesNASDAQ:CLRBEton PharmaceuticalsNASDAQ:ETONBenitec BiopharmaNASDAQ:BNTCAclaris TherapeuticsNASDAQ:ACRSPMV PharmaceuticalsNASDAQ:PMVPView All CompetitorsInsiders & InstitutionsAWM Investment Company Inc.Bought 200,000 shares on 5/16/2024Ownership: 0.486%Acadian Asset Management LLCBought 368,831 shares on 5/10/2024Ownership: 0.896%Rosalind Advisors Inc.Sold 77,973 shares on 4/25/2024Ownership: 3.666%Holdings A/S NovoSold 359,979 sharesTotal: $262,784.67 ($0.73/share)Holdings A/S NovoSold 842,020 sharesTotal: $648,355.40 ($0.77/share)View All Insider TransactionsView All Institutional Transactions SPRB Stock Analysis - Frequently Asked Questions How have SPRB shares performed this year? Spruce Biosciences' stock was trading at $2.93 at the start of the year. Since then, SPRB stock has decreased by 80.5% and is now trading at $0.5717. View the best growth stocks for 2024 here. How were Spruce Biosciences' earnings last quarter? Spruce Biosciences, Inc. (NASDAQ:SPRB) posted its quarterly earnings data on Monday, May, 13th. The company reported ($0.28) EPS for the quarter, beating the consensus estimate of ($0.32) by $0.04. The firm earned $2 million during the quarter, compared to analysts' expectations of $1.12 million. Spruce Biosciences had a negative trailing twelve-month return on equity of 57.53% and a negative net margin of 461.67%. When did Spruce Biosciences IPO? Spruce Biosciences (SPRB) raised $75 million in an initial public offering on Friday, October 9th 2020. The company issued 5,000,000 shares at $14.00-$16.00 per share. Cowen, SVB Leerink, Credit Suisse and RBC Capital Markets served as the underwriters for the IPO. How do I buy shares of Spruce Biosciences? Shares of SPRB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:SPRB) was last updated on 7/8/2024 by MarketBeat.com Staff From Our PartnersWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredI’m giving you the name of this investment for freeThis key unlocks a new pathway to wealth that has been kept hidden from you for decades. In my new documen...Porter & Company | SponsoredOperation Replace Biden is a GoLast night’s debate proved me right: Joe Biden will be replaced. I’ve been making this warning for months… ...The Freeport Society | SponsoredBiden to drop out; finish out his term?On November 16, 2023… Joe Biden accidentally revealed the name of the candidate… Who will replace him in...Paradigm Press | SponsoredExposed: 3 CENT Crypto to Explode June 24th?Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredNvidia’s Quiet $1 Trillion PivotNvidia recently added $277 billion in market cap … IN ONE DAY.Weiss Ratings | SponsoredThe asset beating inflation by 4xCentral Bank Gold Heist In Progress Central banks are buying gold at record rates... and billionaire invest...Colonial Metals | SponsoredObama’s DNC coupAs we approach the Democratic National Convention in August... many sense a Biden swap-out is looming. In f...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Spruce Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Spruce Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
